The Food and Drug Administration (FDA) has approved Amvuttra ® (vutrisiran) for the treatment of the cardiomyopathy of ...

CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

Intellia Therapeutics NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation ...

BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...

Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

Explore top treatments to tackle stubborn fungal nail infections, with expert guidance from podiatrist Tamara Guerreiro Iglesias. The Standard's journalism is supported by our readers. When you ...

Mr. Modore is one of thousands of Kenyans, and hundreds of thousands of people worldwide, with TB who have lost access to treatments and testing in the weeks since the Trump administration slashed ...

as a treatment for patients diagnosed with Duchenne muscular dystrophy ("DMD") cardiomyopathy. The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act ("PDUFA") target ...